ReviewNature reviews. Rheumatology2025
Emerging therapies for the treatment of systemic sclerosis.
Review in Nature reviews. Rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Novel pleiotropic loci link vascular and immune pathways in systemic sclerosis and primary Raynaud's phenomenon.Rheumatology (Oxford, England) · 2026Pooled it
- From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseases.Annals of medicine · 2026Review
- Inflammatory and total immunoglobulin biomarker domains in systemic sclerosis vasculopathy: a phenotype-based cross-sectional study.Clinical rheumatology · 2026Article
- [Survey of care situation for patients with systemic lupus erythematosus and systemic sclerosis with pulmonary involvement in Rhineland-Palatinate and Saarland].Zeitschrift fur Rheumatologie · 2026Article
- Mechanisms of fibrosis and novel antifibrotic therapies.EULAR rheumatology open · 2026Review
- Real-world treatment patterns and determinants of therapy in systemic sclerosis: findings from the German Network for SSc cohort.Arthritis research & therapy · 2026Article
- Assessment of disease severity in systemic sclerosis-associated interstitial lung disease using a modified lung ultrasound score: correlation with pulmonary function, HRCT, and clinical scores, and evaluation of diagnostic efficacy.Clinical rheumatology · 2026Article
- CD8MedComm · 2026Review
- Mechanisms of fibrotic tissue remodelling: insights from systemic sclerosis.Nature reviews. Rheumatology · 2026Review
- The future of autologous stem cell transplantation in systemic sclerosis.Nature reviews. Rheumatology · 2026Article
- Beyond the skin: unmasking oral telangiectasias in limited cutaneous systemic sclerosis.Clinical rheumatology · 2026Article
- Tissue-specific oxidative stress and bleomycin hydrolase signatures are associated with organ-specific fibrotic responses in a mouse model of systemic sclerosis.Frontiers in cell and developmental biology · 2026Article
- Efficacy and safety of autologous hematopoietic stem cell transplantation for refractory systemic sclerosis after rituximab-bendamustine conditioning.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is an autoimmune disease in which fibrotic, vascular, autoimmune and fibrotic mechanisms synergize to promote disease progression. SSc is associated with high morbidity and mortality, primarily owing to fibrotic tissue remodelling and subsequent organ failure. Despite progress with the approval of novel therapies, mortality remains high; approximately half of the people diagnosed with SSc will succumb to disease. This statistic highlights the considerable need for novel, effective therapies. Indeed, SSc has become a disease with very active drug development. Numerous drugs with different modes of actions are currently evaluated in or are about to enter clinical trials in SSc. These clinical trials provide hope for effectively slowing or even halting the progression of fibrosis and thereby further improving outcomes for patients with SSc.
Indexed as
Identifiers
40921742What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.